Drug Trial Radar · NCT03126916
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
May 14, 2018
Primary completion
Sep 30, 2030
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Apr 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 365 days, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Conditions
- Ganglioneuroblastoma
- Ganglioneuroblastoma, Nodular
- Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell TransplantationProcedure
Undergo autologous HSCT
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow Aspiration and BiopsyProcedure
Undergo bone marrow aspiration and biopsy
BusulfanDrug
Given IV
CarboplatinDrug
Given IV
CisplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT scan
CyclophosphamideDrug
Given IV
Dexrazoxane HydrochlorideDrug
Given IV
DinutuximabBiological
Given IV
Doxorubicin HydrochlorideDrug
Given IV
Echocardiography TestProcedure
Undergo echocardiography
Etoposide PhosphateDrug
Given IV
External Beam Radiation TherapyRadiation
Undergo EBRT
Iobenguane I-123Radiation
Given 123 I-MIBG
Iobenguane I-131Radiation
Given IV
IsotretinoinDrug
Given PO
LorlatinibDrug
Given PO
Magnetic Resonance ImagingProcedure
Undergo MRI
Melphalan HydrochlorideDrug
Given IV
Multigated Acquisition ScanProcedure
Undergo MUGA scan
Positron Emission TomographyProcedure
Undergo PET scan
SargramostimBiological
Given SC
Therapeutic Conventional SurgeryProcedure
Undergo standard of care surgery
ThiotepaDrug
Given IV
Topotecan HydrochlorideDrug
Given IV
Vincristine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event free survival (EFS) (Arm A, B, D, and E)Time frame: 3 years
Locations
164 sites in 3 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama · Recruiting
Phoenix Childrens Hospital
Phoenix, Arizona · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Kaiser Permanente Downey Medical Center
Downey, California · Recruiting
Loma Linda University Medical Center
Loma Linda, California · Recruiting
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
Mattel Children's Hospital UCLA
Los Angeles, California · Recruiting
Valley Children's Hospital
Madera, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Children's Hospital of Orange County
Orange, California · Recruiting
Lucile Packard Children's Hospital Stanford University
Palo Alto, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Rady Children's Hospital - San Diego
San Diego, California · Recruiting
Naval Medical Center -San Diego
San Diego, California · Recruiting
UCSF Medical Center-Mission Bay
San Francisco, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado · Recruiting
Connecticut Children's Medical Center
Hartford, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Alfred I duPont Hospital for Children
Wilmington, Delaware · Recruiting
Children's National Medical Center
Washington D.C., District of Columbia · Recruiting
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida · Recruiting
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida · Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
AdventHealth Orlando
Orlando, Florida · Recruiting
Nemours Children's Hospital
Orlando, Florida · Recruiting
Johns Hopkins All Children's Hospital
St. Petersburg, Florida · Recruiting
Saint Mary's Medical Center
West Palm Beach, Florida · Recruiting
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia · Recruiting
Memorial Health University Medical Center
Savannah, Georgia · Recruiting
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii · Suspended
Saint Luke's Cancer Institute - Boise
Boise, Idaho · Recruiting
Lurie Children's Hospital-Chicago
Chicago, Illinois · Recruiting
University of Illinois
Chicago, Illinois · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
Advocate Children's Hospital-Oak Lawn
Oak Lawn, Illinois · Recruiting
Advocate Children's Hospital-Park Ridge
Park Ridge, Illinois · Recruiting
Showing 40 of 164 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.